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Purpose: To initiate a prospective study of glaucoma in a Greek village reported over 30 years ago to have several large
families with primary open-angle glaucoma (POAG).
Methods: A random group of 126 villagers from Taxiarchis, Greece was examined in the village community center. The
detailed evaluation included ophthalmic and general history, measurement of blood pressure, intraocular pressure (IOP),
and central corneal thickness (CCT) as well as evaluation of the optic nerve status.
Results: The incidence of glaucoma approached 18% in this small isolated village. Myocilin variants were present in
almost half of the individuals screened with Arg76Lys and Thr377Met being the most common finding (25% and 17%,
respectively). Over half of the individuals with the Thr377Met mutation were diagnosed with glaucoma. Two of these
patients  were  homozygous  for  the  Thr377Met  mutation.  Three  individuals  with  the  Arg76Lys  polymorphism  had
glaucoma; however, two of these individuals also had the Thr377Met mutation. Only two patients with pseudoexfoliation
were identified.
Conclusions: The incidence of glaucoma and the Thr377Met MYOC mutation in this population is much higher than that
reported for other European populations.
Glaucoma  is  a  common  blinding  disease  that  was
originally described in Greece around 500 BC. In ancient
Greece,  Aristotle  and  Hippocrates  treated  patients  with
“glaucosis,” associated with the gray-green color of the pupil
in  the  last  stages  of  glaucoma  [1].  Today,  glaucoma  is
recognized as a group of eye diseases resulting from optic
nerve damage. Primary open-angle glaucoma (POAG) is the
most common form of glaucoma in the United States, Europe,
and Australia comprising 75%–95% of the glaucoma cases
[2].  Population-based  studies  of  POAG  in  Europe  have
reported prevalence rates ranging from 1.1% in the Rotterdam
Study [3] to 3.8% in the Thessaloniki Eye Study [4].
Exfoliative glaucoma (XFG) is a secondary glaucoma
that is found in high frequency in certain regions of Europe.
This disease is characterized by flakes of granular material at
the  pupillary  margin  of  the  iris  and  throughout  the  inner
surface of the anterior chamber. The prevalence of XFG is
extremely high in the Scandinavian countries and in Greece
[4-7].  Recently,  an  association  of  a  single  nucleotide
polymorphism (SNP) in the LOXL1 gene with exfoliation was
identified in the Icelandic population [8].
Taxiarchis, a small village in northern Greece with 1,100
inhabitants,  was  considered  to  have  a  surprisingly  high
incidence of glaucoma [9]. This isolated population located
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on Mount Holomondas appeared to be enriched for familial
glaucoma. In the only previous attempt to investigate the
problem,  Georgiades  et  al.  [9]  examined  a  cohort  of  the
villagers  and  identified  20  individuals  with  glaucoma.
Fourteen  of  the  individuals  were  from  one  large  family
comprised  of  five  generations  with  a  clear  autosomal
dominant inheritance pattern of POAG. Only two of the 20
individuals with glaucoma were sporadic cases.
Mutations in myocilin (MYOC), the first POAG gene to
be identified, have been found in approximately 4% of POAG
patients (Myocilin allele-specific phenotype database) [10].
The  Thr377Met  MYOC  mutation  has  been  identified  in
several ethnic groups from Greece, Britain, Finland, India,
Australia and the United States [11-17]. Distinct haplotypes
are  associated  with  the  Thr377Met  MYOC  mutation,
suggesting that this mutation has arisen independently at least
three times [11]. To date, all individuals of Greek ancestry
with  the  Thr377Met  MYOC  mutation  share  the  same
haplotype, suggesting a common founder for these families.
The clinical phenotype of the Thr377Met MYOC variant
is  intermediate  between  the  more  aggressive  and  severe
glaucoma found in patients with the Pro370Leu mutation and
the mild presentation of the Glu368Stop mutation. The age of
onset in patients with the Thr377Met ranges from 14 to 66
years [12,17].
The Arg76Lys variation in MYOC appears to be a non-
disease-causing single nucleotide polymorphism (SNP; at the
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774Myocilin  allele-specific  phenotype  database)  [18,19].  The
designation of this SNP as not being a factor in POAG is based
upon the similar frequency of the alleles in control and patient
populations  as  well  as  the  conservation  of  charge  of  the
arginine and lysine amino acids. In addition, the Arg76Lys
change has been reported to segregate with the non-disease
haplotype in a POAG family [20]. Thus, the Arg76Lys variant
is considered to be a normal non-disease-causing SNP.
Based upon the high reported incidence of glaucoma in
Taxiarchis  and  our  previous  findings  of  the  Thr377Met
MYOC mutation in the Greek population [11], we undertook
a community-based study to determine if this variant was
present in this village.
METHODS
A  random  group  of  126  villagers  in  Taxiarchis  was
interviewed and examined after obtaining informed consent
following the protocol approved by the Bioethics Committee
of the Medical School of Aristotle University of Thessaloniki.
The principles of the Declaration of Helsinki were followed.
The  interview  included  familial  and  personal  histories  of
glaucoma. The detailed evaluation at the community center in
Taxiarchis  included  ophthalmic  and  general  history,
measurement of blood pressure, intraocular pressure (IOP),
central corneal thickness (CCT), and evaluation of the optic
nerve  status.  Slit-lamp  biomicroscopy  was  performed  in
selected cases. IOP was measured with two recently calibrated
Reichert  TONO-PEN®  XL  Applanation  Tonometers
(Reichert  Ophthalmic  Instruments,   Depew,  NY).  Optic
nerve cupping was evaluated using a direct ophthalmoscope
in  an  undilated  state.  Pachymetry  with  an  ultrasound
Pachmate DGH55 instrument (DGH Technology, Exton, PA)
was used to determine the CCT for each eye. The purpose of
the on-site clinical screening was not to make a definitive
diagnosis  but  rather  to  decide  who  to  refer  for  further
investigation based upon high IOPs and/or suspicious optic
nerve appearance. Glaucoma classification was based upon
characteristic glaucomatous optic nerve findings such as cup
to disk ratios of 0.6 or greater (a cup to disk ratio of 0.6 is
defined as glaucomatous in Greece [21]) in one or both eyes,
asymmetry of cup to disk ratios of 0.2 or greater, and erosion
or notching of rims. Individuals were classified as glaucoma
suspects whenever characteristics such as violation of the
inferior, superior, nasal, and temporal (ISNT) rule, asymmetry
in cupping, a focal notch in the nerve, or IOP greater than
21  mmHg  were  present  [22].  In  our  initial  screen,  the
diagnosis of the glaucoma suspect was a means of referring
the  patient  for  more  definitive  study.  Venous  blood  was
obtained for DNA extraction using the standard salting out
methods.
Following the field visit, villagers with a high IOP and
the appearance of glaucomatous disc damage were given a
comprehensive  exam  at  the  Glaucoma  Unit  of  the  1st
University,  Department  of  Ophthalmology,  American
Hellenic  Educational  Progressive  Association  (AHEPA)
Hospital,  Thessaloniki,  Greece.  Patients  underwent  best
corrected distance Snellen visual acuity assessment, corneal
pachymetry, a reliable visual field (<30% fixation losses, false
positives and negatives) with Humphrey 24–2, gonioscopy-
detailed assessment of anterior and posterior segments before
and  after  dilatation  of  the  pupil,  and  a  scanning  laser
polarimetry with variable corneal compensation (GDX VCC)
exam when possible. Two separate IOP measurements were
conducted at this visit between 11:00 AM and 1:00 PM All
patients underwent a detailed assessment for the presence of
exfoliation after pupillary dilation. Several exfoliation-related
clinical  signs  were  recorded  in  an  attempt  to  create  a
“phenotype score.”
Following  the  comprehensive  hospital  exam,  patients
were  divided  into  four  groups-glaucoma,  suspicion  for
glaucoma,  ocular  hypertensive  (OHT),  and  normal.  The
definition of glaucoma in this investigation adhered to the
AAO  Preferred  Practice  Patters  criteria-at  least  one  IOP
measurement of 22 mmHg or more (if the IOP was never
greater  that  22  mmHg,  it  was  considered  low  tension
glaucoma), reproducible visual field damage, pathologic optic
nerve cupping, violation of the ISNT rule, and cup-to-disc
ratio of 0.6 or greater. During the comprehensive exam, disc
size was measured with a Volk stereoscopic lens and taken
into consideration.
Myocilin screening: The promoter region and exons 1–3
of  MYOC  were  sequenced  at  the  Portland  Veterans
Administration Medical Center (Portland, OR) as previously
described [23]. Microsatellite marker analysis in the GLC1A
region including D1S452, D1S1619, D1S2790, and D1S242
was performed at deCODE (Reykjavik, Iceland)
Figure 1. Segregation of primary open-angle glaucoma in a large
family from Taxiarchis (Taxi 2). Note that A23 is homozygous for
the Thr377Met mutation. A filled-in symbol indicates that the person
has been diagnosed with POAG. The number under the symbol
indicates  the  specific  code  given  to  the  family  member  who
participated in the study. The MYOC genotype is denoted below the
code. The arrow indicates the proband for the pedigree.
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One  hundred  and  twenty-six  villagers  in  Taxiarchis  were
examined for glaucoma. The age of exam represents the age
of diagnosis for those individuals with glaucoma since this
was the first time that they had been examined. The average
age of the people in the study was 60 years and ranged from
8 to 90 years old. Twenty-one of the 126 villagers examined
(16%) were diagnosed as having glaucoma, and 10 of the
villagers  (7%)  examined  were  diagnosed  as  glaucoma
suspects. The highest recorded IOP was 65 and 36 mmHg in
the  right  and  left  eye,  respectively.  Family  trees  were
constructed  based  upon  the  information  given  by  the
participants.  Seventeen  of  the  villagers  diagnosed  with
glaucoma were from five families with at least two or more
affected individuals. The remaining four glaucoma patients
were isolated cases.
During  the  subsequent  comprehensive  exam  at  the
Department  of  Ophthalmology  of  1st  University  in
Thessaloniki, Greece, 34 of the villagers were reexamined
including 20 of the 21 villagers with glaucoma. The diagnosis
of POAG was confirmed in all 20 of these individuals. The
classification of two of the suspects was changed to POAG
without knowledge of their MYOC genotype. Twenty-two
villagers (17%) were confirmed as having glaucoma, six (4%)
were classified as glaucoma suspects, and three (2%) were
reclassified  as  ocular  hypertensives.  Only  2  of  the  23
individuals with glaucoma had XFG. Two of the patients (A6
OS and A15 OD) had trabeculectomies with mitomycin C
after the study visit. Patient A9 had bilateral insertion of
Glaukos stents.
Myocilin genotype: Sequencing of the three exons and
promoter of MYOC in 124 of the villagers identified four
Figure 2. . Segregation of primary open-angle glaucoma and the
Thr377Met MYOC mutation in a large family from Taxiarchis (Taxi
1). A filled-in symbol indicates that the person has been diagnosed
with POAG. The number under the symbol indicates the specific
code given to the family member who participated in the study. The
MYOC genotype is denoted below the code. The arrow indicates the
proband for the pedigree.
MYOC  variants,  Thr377Met,  Arg76Lys,  Tyr347Tyr,  and
Thr438Thr  (see  Table  1).  The  Arg76Lys  was  the  most
common  with  its  presence  in  31  people;  21  individuals
possessed the Thr377Met variant; seven had the Tyr347Tyr;
and one individual had the Thr438Thr polymorphism. Of the
124 villagers screened, 55 villagers possessed one or more of
the above MYOC variants (see Table 1).
Of the 21 individuals with the Thr377Met variant, 13
were diagnosed with POAG and two had OHT. One person
with normal IOP and cup to disc ratios had a visual field
consistent with POAG and was classified as a suspect (see
Table 2). Two individuals (A23 and A126) were homozygous
for the Thr377Met mutation, and both had POAG. A23 had
the  highest  recorded  IOP  (65  mmHg  OD).  At  the
comprehensive  reexamination  at  the  1st  University
Department of Ophthalmology in Thessaloniki, Greece, the
IOP in his right eye was still high at 60 mmHg. Both of his
parents were deceased. His sister who also had glaucoma did
not have the Thr377Met variant (see Figure 1). The other
villager who was homozygous for the Thr377Met mutation
(A126) was 16 years old at the time of examination; she had
pressures of 25 OU and asymmetric cup to disc ratios with
visual field loss in the right eye. Her mother was 51 years old
at  the  time  of  examination  and  had  normal  pressures
(17 mmHg OU) with cup to disc ratios of 0.3 OU. She had the
Thr377Met variant as expected but does not have glaucoma
at  this  time.  The  father  of  A126  was  not  available  for
examination. The seven individuals with normal cup to disc
ratios and IOPs ranged in age from 45 to 90 years old. No signs
of  exfoliation  were  found  in  the  15  individuals  with  the
Thr377Met  variant  examined  at  the  University  of
Thessaloniki. The incidence of the Thr377Met MYOC variant
in the glaucoma patients was 59% (13/22).
The Arg76Lys polymorphism was found in 31 of the 123
screened villagers. Three of these individuals were diagnosed
with POAG; two of them also had the Thr377Met mutation
(see  Table  3).  The  same  individual  described  above  with
normal cup to disc ratios and IOPs and an abnormal visual
field had both the Arg76Lys and the Thr377Met variations.
The other 27 subjects had only the Arg76Lys polymorphism
with  the   exception  of  one   individual   who  also  had  the
Thr438Thr variant.  One  individual with  IOPs of 26 and 20
mmHg   in   the   right   and   left    eye,    respectively,   was
reclassified from normal to OHT.  Normal  cup  to  disc ratios
and IOPs were found in  the remaining 26 individuals whose
ages ranged from 17 to 81 years.
Ten villagers who were diagnosed with glaucoma had
normal MYOC sequences, although one had the Tyr347Tyr
polymorphism. This person also had exfoliation. Their ages
ranged from 49 to 80 years. The maximum IOP in this group
was  36  mmHg.  Four  individuals  with  normal  MYOC
sequences were classified as suspects based either upon high
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0.5–0.6.
Five families were identified with two or more
individuals with glaucoma. Four families possessed the
Thr377Met variation. In the first family, all three individuals
with the Thr377Met mutation have glaucoma including A23
who is homozygous for this variant. His sister, A75, also has
POAG but has the Tyr347Tyr polymorphism not the
Thr377Met variant (see Figure 1). In the second family (see
Figure 2), six individuals have POAG, but only five of these
have the Thr377Met mutation. In addition, one individual in
the older generation (A50) has the Thr377Met variant but had
normal ocular findings when examined at the age of 70. Only
one of these families (data not shown) had clean segregation
of glaucoma with the Thr377Met mutation. The other three
families each had one individual with glaucoma with the
normal Thr377Thr MYOC sequence. Analysis of the
haplotype showed that all of the individuals from
Taxiarchis with the Thr377Met MYOC variant shared the
haplotype previously reported in Greek families (not shown)
[11].
DISCUSSION
This small Greek village appears to have a high prevalence of
glaucoma (22 out of 126 individuals) approaching 18%. This
was a self-selected study so the findings may be biased by
individuals with known glaucoma being more likely to enroll
in the study. We are in the process of examining all of the
villagers to determine the actual prevalence of glaucoma in
this village. The Thr377Met MYOC mutation was identified
in over half of the glaucoma patients. The incidence of
MYOC mutations in unselected glaucoma patients reportedly
ranges between 3%–5% in other populations [10,19,24].
Higher incidences of MYOC mutations are found in juvenile
glaucoma and mixed-onset primary open-angle glaucoma
families (30%–33%) [14].
Theageoftheglaucomapatientsreflectedthepreviously
reported age ranges for MYOC mutations. The youngest
patient was 16 years old and was homozygous for the
Thr377Met mutation. The remaining glaucoma patients
ranged in age from 36 to 82 years.
In the previous paper reporting the high incidence of
familial glaucoma in this village [9], 14 of the 20 individuals
diagnosed with glaucoma were from one family. In this study
with the information provided to us by the villagers, we
identified five different families with glaucoma. Considering
that the Thr377Met MYOC variant was segregating through
four of these families and all individuals with the variant
shared the same haplotype, these four families are probably
related at some point farther back in their history. Further
genealogical work will be required to identify the common
ancestor for these individuals.
Aconfoundingfactoringlaucomaisthepresenceinsome
patients of exfoliation syndrome, which is characterized by
the development of white, dandruff-like flakes on anterior
segment structures [25]. In the eastern Mediterranean
countries, the prevalence of exfoliation in glaucoma cohorts
ranges from 25%–47%. In Greece, Konstas and Allen [5]
reported that 87% of glaucoma patients undergoing
trabeculectomy had exfoliation. Our finding of only two
patients with exfoliation in this glaucoma cohort is
noteworthyconsideringthatthisdiseaseisextremelycommon
in Greece.
Theclinicalpresentationofthetwopatientshomozygous
for the Thr377MetMYOC mutation is much more severe than
that of the heterozygous subjects. Typically, patients with
only one copy of the Thr377Met mutation are diagnosed in
their fourth decade with maximum IOPs around 30 mmHg
[11]. In this study, one of the homozygotes was diagnosed at
the age of 16 with difficult to control IOPs. The second
villager, also homozygous for the Thr377Met mutation, had
anIOPof65mmHginhisrighteyeatthetimeofexamination
TABLE 1. SUMMARY OF MYOC VARIANTS AND CLINICAL PRESENTATION IN VILLAGERS.
Genotype
Number of villagers with phenotype
POAG Total
Thr377Met 9 1 6 16
Thr377Met/Thr377Met 2 2
Thr377Met/Arg76Lys 2 1 3
Arg76Lys 1 1 25 27
Arg76Lys/Thr438Thr 1 1
Tyr347Tyr 1 1 4 6
Wild Type 8 1 4 56 69
Not Genotyped 1 1 2
Total 21 1 2 3 6 93 126
Summary of MYOC variants and ocular findings in 126 villagers from Taxiarchis, Greece. POAG indicates primary open angle
glaucoma; OHT indicates ocular hypertension. The asterisk indicates that the patient has not had a comprehensive examination
to rule out exfoliation glaucoma.
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Glaucoma* Exfoliation OHT Suspect Normalwith no vision left in that eye. Thus, the major impact of
homozygosity for the Thr377Met MYOC mutation appears to
be extremely high and difficult to control pressures.
Homozygosity  of  three  different  MYOC  variants,
Lys423Glu, Gln368 STOP, and Arg46STOP, has previously
been  reported  [26-28].  The  Lys423Glu  variant  in  the
heterozygous  state  usually  presents  with  severe  glaucoma
before the age of 40. Normal ocular findings were found in
four  siblings  who  were  homozygous  for  the  Lys423Glu
variant [26]. Hewitt et al. [27] reported a subject that was
homozygous  for  the  Gln368STOP  MYOC  mutation  with
normal ocular findings at the age of 49. In the last case, a
Korean proband, homozygous for the Arg46STOP mutation,
presented  with  a  severe  glaucoma  phenotype  while  her
heterozygous relatives did not exhibit any glaucomatous signs
[29].  The  frequency  of  the  Arg46STOP  variant  has  been
shown to be similar in glaucomatous (2.0%) and matched
control cohorts (2.2%), suggesting that this sequence variant
is likely to be a neutral variant in the heterozygous state [30].
Our findings show that the Thr377Met MYOC homozygous
state results in a more severe glaucoma phenotype than the
heterozygous  condition.  This  stands  in  contrast  to  the
Lys423Glu  and  Gln368STOP  homozygotes,  which  have
normal ocular features.
The above findings suggest that the Thr377 position has
a unique function in MYOC. The Thr377 site in the myocilin
protein may be phosphorylated by casein kinase II (CK2)
[31,32]. CK2 is a ubiquitous, highly pleiotropic, constitutively
active Ser/Thr protein kinase that phosphorylates over 300
protein substrates with an S/T-x-x-D/E motif. The substitution
of the Thr377 with Met in the myocilin protein potentially
results in loss of phosphorylation of this site. Three different
scenarios  potentially  impacted  by  CK2  phosphorylation
include  the  stabilization  of  helix  unfolding,  inhibition  of
caspase cleavage, which shares the E/D-x-D recognition motif
of CK2, and inhibition of protein–protein adhesion modules
[31,33,34].  Future  research  investigating  the  properties  of
mutant myocilin, which replaces threonine at position 377
with  methionine,  will  be  required  to  determine  the  exact
mechanism  for  the  more  severe  presentation  in  the
homozygote compared to the heterozygote.
Caspase cleavage of the D-I-D motif (residues 378–380)
in the Thr377Met homozygote would result in the release of
the carboxyl peptide. In the Glu368STOP homozygote, this
TABLE 2. CLINICAL FINDINGS IN VILLAGERS WITH THE THR377MET MYOC VARIANT.
Code number Age IOP OD/OS CCT OD/OS C/D OD/OS Visual field
loss
Status MYOC variation
A33 52 17/18 0.531/.534 0.45/0.45 yes POAG Thr377Met
A14 60 18/18 0.488/.491 0.6/0.5 yes POAG Thr377Met
A15 82 42/24 0.502/502 0.9/0.9 Yes POAG Thr377Met
A16 56 19/27 0.554/.567 0.6/0.65 yes POAG Thr377Met
A58 55 33/28 0.520/.526 0.9/0.8 yes POAG Thr377Met
A23 68 65/24 0.573/.587 0.94/0.99 yes POAG Thr377Met/
Thr377Met
A6 72 18/19 0.542/.539 0.99/ 0.99 yes POAG Thr377Met
A54 74 42/21 0.536/.557 0.9/0.85 yes POAG Thr377Met/
Arg76Lys
A34 71 15/15 0.545/.536 0.90/0.75 yes POAG Thr377Met
A42 74 8/10 0.533/.545 0.85/0.85 yes POAG Thr377Met
A31 71 20/17 0.509/.528 0.6/0.6 yes POAG Thr377Met/
Arg76Lys
A126 16 25/25 0.556/.557 0.6/0.45 yes OD POAG Thr377Met/
Thr377Met
A107 65 24/25 0.612/.610 0.2/0.2 ND OHT Thr377Met
A40 43 22/22 0.565/.601 0.3/0.3 no OHT Thr377Met
A25 36 22/20 0.630/.585 0.5/0.4 no POAG Thr377Met
A3 72 22/24 0.556/.553 0.5/0.6 yes Suspect Thr377Met/
Arg76Lys
A21 90 12/12 0.543/.588 0.2/0.2 ND Normal Thr377Met
A50 70 12/13 0.572/.565 0.3/0.3 ND Normal Thr377Met
A43 68 21/20 0.553/.528 0.3/0.3 ND Normal Thr377Met
A125 51 17/15 0.559/.567 0.3/0.3 ND Normal Thr377Met
A41 45 18/19 0.598/.591 0.3/0.3 ND Normal Thr377Met
Clinical characteristics of the 21 villagers that were found to have the Thr377Met MYOC variant is displayed; 13 of whom have
POAG. The abbreviations are ND=Not done; OD=right eye; OS=left eye; and C/D=cup-to-disc ratio.
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778peptide  is  absent  due  to  the  deletion.  In  the  Lys423Glu
homozygote, the Thr377 residue is present and available for
phosphorylation  and  thus,  inhibition  of  cleavage  of  the
carboxyl terminus by caspase occurs. Thus, the presence of
the carboxyl peptide in the Thr377Met homozygote but not in
the Glu368STOP or Lys423Glu homozygotes may be the
factor causing the difference in clinical presentation.
Several  groups  have  examined  the  expression  of  the
Gln368STOP, Lys423Glu, and Thr377Met myocilin proteins
[35,36].  Solubility  studies  have  shown  that  all  three
substitutions result in decreased solubility of the protein [36].
Interestingly,  the  Thr377Met  mutant  is  secreted
extracellularly while the Gln368STOP and Lys423Glu mutant
proteins are retained intracellularly [35]. The differences in
presentation  between  the  Thr377Met,  Gln368STOP,  and
Lys423Glu homozygotes may be due to the specific amino
acid  change,  the  position  in  the  protein,  or  the  genetic
background of the individual.
The  incomplete  penetrance  of  the  Thr377Met  MYOC
mutation  has  been  previously  reported  by  several  groups
[12,16,17]. In Finland, a six-generation family with juvenile
open-angle  glaucoma  (JOAG)  and  primary  open-angle
glaucoma (POAG) included 20 individuals heterozygous for
the mutation; however, only nine were glaucomatous [12]. In
Australia, 31 mutation carriers over the age of 18 years were
identified in four POAG pedigrees; 23 of whom had either
TABLE 3. CLINICAL PRESENTATION IN INDIVIDUALS WITH THE ARG76LYS MYOC VARIANT.
Code number
A31 71 20/17 0.509/.528 0.6/0.6 Yes POAG Thr377Met/
Arg76Lys
A54 74 42/21 0.536/.557 0.9 Pale/0.85 Yes POAG Thr377Met/
Arg76Lys
A82 71 20/32 0.528/.501 0.65/0.9 Yes XFG Arg76Lys
A3 72 22/21 0.556/.553 0.3/0.3 Yes Suspect Thr377Met/
Arg76Lys
A49 50 9/11 0.582/.576 0.3/0.3 Not Done Normal Arg76Lys
A51 60 13/13 0.617/.609 0.1/0.1 Not Done Normal Arg76Lys
A26 68 17/17 0.511/.518 0.3/0.3 Not Done Normal Arg76Lys
A27 56 09/10 0.585/.572 0.1/0.2 Not Done Normal Arg76Lys
A29 17 21/21 0.606/.579 0.4/0.4–0.5 Not Done Normal Arg76Lys
A30 64 09/10 0.527/.520 0.3/0.3 Not Done Normal Arg76Lys
A57 39 26/24 0.533/.544 0.4/0.4 No OHT Arg76Lys
A60 50 18/14 0.546/.553 0.1/0.1 Not Done Normal Arg76Lys
A67 64 20/19 0.530/.528 0.3/0.3 Not Done Normal Arg76Lys
A68 52 20/16 0.556/.551 0.2/0.5 Not Done Normal Arg76Lys
A63 80 14/16 0.558/.565 0.3/0.2 Not Done Normal Arg76Lys
A65 81 11/11 0.486/.489 0.2/0.3 Not Done Normal Thr438Thr/
Arg76Lys
A71 63 16/18 0.566/.566 0.3/0.3 Not Done Normal Arg76Lys
A79 83 17/15 0.585/.592 0.3/0.3 Not Done Normal Arg76Lys
A80 61 17/20 0.583/.538 0.4/0.4 Not Done Normal Arg76Lys
A81 34 16/14 0.619/.628 0.3/0.3 Not Done Normal Arg76Lys
A84 70 19/17 0.516/.528 0.3/0.3 Not Done Normal Arg76Lys
A86 78 15/15 0.587/.600 0.2/0.2 Not Done Normal Arg76Lys
A93 34 15/15 0.585/.580 0.35/0.35 Not Done Normal Arg76Lys
A98 58 16/15 0.539/.502 0.3/0.3 Not Done Normal Arg76Lys
A99 59 18/19 0.542/.559 0.2/0.2 Not Done Normal Arg76Lys
A122 31 9/9 0.565/.600 0.3/0.3 Not Done Normal Arg76Lys
A105 70 13/14 0.602/.594 0.2/0.2 Not Done Normal Arg76Lys
A101 59 14/13 0.552/.557 0.1/0.1 Not Done Normal Arg76Lys
A117 54 12/13 0.536/.577 0.1/0.1 Not Done Normal Arg76Lys
A124 34 19/18 0.510/.505 0.2/0.2 Not Done Normal Arg76Lys
A109 70 13/11 0.567/.569 0.3/0.3 Not Done Normal Arg76Lys
Clinical characteristics of the 31 villagers with the nonglaucoma-associated Arg76Lys MYOC variant are shown. Two of the
three individuals with POAG also have the Thr377Met MYOC mutation. The abbreviations are OD=right eye; OS:left eye; 
and C/D=cup-to-disc ratio.
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Age IOP OD/OS CCT OD/OS C/D OD/OS Visual field loss Status MYOC variationOHT or POAG [17]. The families in our study also show
incomplete penetrance of the Thr377Met MYOC mutation,
suggesting that this particular variant is more likely to be a
susceptibility factor than a major glaucoma gene.
Probably the most intriguing finding in this study is the
large number of villagers with the Thr377Met MYOC and
Arg76Lys variants (17% and 25%, respectively). A higher
than expected heterozygote frequency may be explained by
genetic  drift,  increased  fertility,  or  heterozygote  selective
advantage. The high number of villagers with the Thr377Met
MYOC mutation may result from the isolation of the village,
may reflect that the original founder of this mutation was from
this  village,  or  may  be  due  to  selective  advantage  of  the
heterozygous state. Sharing of mutations and high carrier rates
support the premise that the origin of the Thr377Met MYOC
mutation occurred in Taxiarchis and spread from this village
to other regions in Greece and ultimately worldwide.
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